Clene (CLNN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$197,000.00

Revenue (quarter)

$90,000.00

Revenue growth (year over year)

+233.33%

Gross profit (trailing twelve months)

$138,000.00

Gross margin

70.05%

Net income (trailing twelve months)

−$39.5M

Net income (quarter)

−$13.4M

Net income growth (year over year)

−80.94%

Net margin

−20059.90%

Return on equity

—

EPS (trailing twelve months)

−$3.55

Book value per share

−$1.94

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

207.53%

Payout ratio

—

Dividend yield

—

Company profile

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

• Is Clene (CLNN) profitable?

  No. Clene reported a net loss of $39.5M over the trailing twelve months.

• How much revenue does Clene (CLNN) make?

  Clene generated $197,000.00 in revenue over the trailing twelve months, up 233.33% year over year.

• How do I buy stock in Clene (CLNN)?

  CLNN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.